Despite a cut in stock holdings by Amalgamated Bank and trimming of the stock position by the Swiss National Bank and other institutions, Charles River Laboratories posted strong results for Q1 2024, with revenues beating expectations. The company further updated its FY 2024 earning guidance, showcasing a healthy balance sheet. Charles River's strategic SWOT insight highlighted its recovery signs and several positive metrics. The firm sealed multiple agreements to expedite discovery programs and reduce reliance on animal testing. Moreover, they have committed to 100% renewable electricity usage worldwide. Also, Charles River's technology-driven capabilities were showcased at AACR 2024. However, the company has faced investigation allegations put forth by Johnson Fistel LLP.
Charles River Laboratories International CRL News Analytics from Wed, 31 May 2023 07:00:00 GMT to Fri, 10 May 2024 14:11:30 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
